PFIZER INC.
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Safety and Efficacy of Pregabalin in Patients With Diabetic Peripheral Neuropathy.
Phase 3
Completed
- Conditions
- Diabetic Neuropathy, Painful
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2007-08-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 240
- Registration Number
- NCT00141401
CP-481,715 Nickel Allergy Study.
Phase 1
Completed
- Conditions
- Dermatitis, Allergic Contact
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2006-07-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 48
- Registration Number
- NCT00141180
- Locations
- ๐ฉ๐ฐ
Pfizer Investigational Site, Hellerup, Denmark
Assessment of Onset, Safety & Toleration of UK-369,003 in Male Erectile Dysfunction
Phase 2
Completed
- Conditions
- Impotence
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2006-07-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 300
- Registration Number
- NCT00141349
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, Milwaukee, Wisconsin, United States
Efficacy And Safety Of Xalatan Compared To Usual Care In Patients With Open Angle Glaucoma Or Ocular Hypertension.
Phase 4
Completed
- Conditions
- Ocular HypertensionGlaucoma, Open-Angle
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2008-04-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 329
- Registration Number
- NCT00140062
- Locations
- ๐ธ๐ช
Pfizer Investigational Site, Uppsala, Sweden
Olmesartan Alone or in Combination With Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension
Phase 3
Completed
- Conditions
- Essential Hypertension
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2018-12-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 410
- Registration Number
- NCT00139698
- Locations
Pfizer Investigational Site
A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With Asthma
Phase 3
Completed
- Conditions
- AsthmaDiabetes Mellitus
- Interventions
- Drug: Subcutaneous Insulin
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2010-06-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 288
- Registration Number
- NCT00139659
- Locations
- ๐ฉ๐ช
Pfizer Investigational Site, Neuss, Germany
Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer
Phase 3
Completed
- Conditions
- Adenocarcinoma
- Interventions
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2011-05-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 606
- Registration Number
- NCT00140075
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, Milwaukee, Wisconsin, United States
Azithromycin Microspheres in Patients With Low Risk Community Acquired Pneumonia
Phase 3
Completed
- Conditions
- Community-Acquired Pneumonia
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2011-05-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 47
- Registration Number
- NCT00140023
- Locations
- ๐ต๐ญ
Pfizer Investigational Site, Quezon City, Philippines
Depo-Provera: Bone Mineral Density and Total Body Calcium in Adolescent DP150CI Users and Non-Hormonal Contraception
Phase 4
Completed
- Conditions
- ContraceptionBone Density
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2008-09-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 350
- Registration Number
- NCT00139685
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, Norfolk, Virginia, United States
A Study To Investigate The Effect Of PD-217,014 On Abdominal Pain/Discomfort In Patients With IBS.
Phase 2
Completed
- Conditions
- Irritable Bowel Syndrome
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2008-06-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 330
- Registration Number
- NCT00139672
ยฉ Copyright 2025. All Rights Reserved by MedPath